Navigation Links
Sanofi US and POZEN Sign Exclusive License Agreement for the Commercialization of PA8140/PA32540 Tablets in the U.S.
Date:9/4/2013

opment and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca for the sales and marketing of VIMOVO®; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended March 31, 2013. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.Contact:Sanofi USCarrie Brown(908) 981 6486Carrie.brown@sanofi.com POZEN Inc.Bill Hodges

Stephanie BonestellChief Financial Officer

Manager, Investor Relations and Public Relations(919) 913 1030

(919) 913 1030

SOURCE Sanofi US
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteurs Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older
2. Sanofi Pasteur Announces Shipment of First Lots of 2013-2014 Seasonal Influenza Vaccine in U.S.
3. Sanofi US and Joslin Diabetes Center Announce Results from Multicultural Outreach Pilot at American Diabetes Association Scientific Sessions
4. Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
5. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
6. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
7. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
8. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
9. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
10. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
11. NextBio Announces Translational Medicine Partnership with Sanofi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)...  IRIDEX Corporation (NASDAQ: IRIX ) today announced ... results after the market closes on Thursday, May ... Company will host a conference call with the investment ... Thursday, May 7, 2015 to discuss the ... Interested parties may access the live conference call ...
(Date:4/30/2015)...   Regulus Therapeutics Inc . (NASDAQ: RGLS ... of innovative medicines targeting microRNAs, today announced that it ... ended March 31, 2015 on Thursday, May 7, 2015, ... Regulus will host a conference call and webcast on ... Time to discuss its first quarter 2015 financial results ...
(Date:4/30/2015)... FRANCISCO, April 30, 2015  Nektar Therapeutics (Nasdaq: ... first quarter ended March 31, 2015. ... 2015 were $325.8 million as compared to $262.8 million ... marketable securities at March 31, 2015 includes a $100.0 ... for the first commercial sale of Movantik™(naloxegol) in the ...
Breaking Medicine Technology:IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 2Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 4Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 5Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 6Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 7Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 8Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 9Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 10Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 11Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 12
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... the Jefferies 2012 Global Healthcare Conference in New York, NY. ... Presentation date: Monday, June 4, 2012 , Presentation time: 12:30 ... 30-day archive of these presentations will be available at http://ir.avanir.com ...
... - Hospital Universitari Vall d,Hebron Research Institute in Barcelona ... an open label phase 2 study evaluating the overall ... treatment of cirrhosis of the liver and upper GI ... patients demonstrated that OCR-002 is well tolerated and provided ...
Cached Medicine Technology:Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 2Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 3
(Date:5/2/2015)... 02, 2015 On Tuesday April 7th, ... (ELCH) gathered to celebrate improvements in patient care. In ... Partners (RVHP), had zero acquired ventilator associated infections, zero ... infections. ELCH was also recently named a Top Performer ... at ELCH credited the teamwork of staff from all ...
(Date:5/2/2015)... success that Veatch Dental Consulting has had over the years, ... Shields to the team. With Neida and Alex on board, ... working with dentists to ensure their success. , Neida Miranda ... She was certified as dental assistant from Texas State Technical ... the importance of oral hygiene to patients, Neida was moved ...
(Date:5/1/2015)... Jusuru International has been awarded the ... of its flagship nutritional supplement, Liquid BioCell™ Life, and ... name, new logo, new packaging, new products, and new ... to identify and promote programs that serve as examples ... congratulates Jusuru International for their outstanding accomplishments and contributions ...
(Date:5/1/2015)... It’s raining bills on Capitol Hill with members in ... support for telemedicine. , “Such action is unprecedented ... Congress,” said Jonathan Linkous, CEO of the American Telemedicine Association ... to embrace the use of telecommunications in the delivery of ... mission to improve quality, access, equity and affordability of healthcare.”, ...
(Date:5/1/2015)... The Quail Creek Relay for Life Team raised over $89,000 ... Creek Relay team has raised almost $860,000. Quail Creek ... their biggest event, January’s Dinner and Auction; an annual Putting ... Relay for Life team was established to honor a member’s ... “I was hooked when I learned how the money raised ...
Breaking Medicine News(10 mins):Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2
... , MALVERN, Pa., Aug. 18 ... Siemens Healthcare,s SOMATOM(R) Emotion CT scanner is ... and cost-effective, the SOMATOM Emotion 16 enables facilities to not only ... also undertake high-end, detailed examinations, such as high-resolution CT angiography, which ...
... tool, researcher says , TUESDAY, Aug. 18 (HealthDay News) ... early pancreatic cancer, a new study suggests. , Prion ... known about prions outside of the brain. This ... tumors to grow more aggressively, said researchers at Case ...
... Aug. 18 VirtualHealth Technologies, Inc. (OTC Bulletin Board: ... Secure eHealth, LLC, recently received a patent as well ... and apparatus of portable information agents. The ... methodology and apparatus for a "portable information agent" which ...
... MINNEAPOLIS, Aug. 18 GoldenCare USA and American Independent ... care products from United of Omaha Life Insurance Company, a Mutual ... affordable rates. , , Cash benefit policies have ... viewed as too expensive. Now, United of Omaha makes cash benefit ...
... , , ... launched a T-shirt design competition offering the chance to combine creativity with ... Cure(R). Through Oct. 26, 2009, participants can enter Passionately Pink-inspired T-shirt ... win a weekly drawing for a $100 Hanes gift card. ...
... SAN DIEGO, Aug. 18 Aethlon Medical, Inc. ... at today,s 14th Annual Southern California Investor Conference being ... The conference is hosted by California Equity Research and ... life science, technology, media, and real estate/financial organizations. ...
Cached Medicine News:Health News:Siemens Emotion CT Receives Top Rating in KLAS Report 2Health News:Siemens Emotion CT Receives Top Rating in KLAS Report 3Health News:Abnormal Protein May Signal Pancreatic Cancer 2Health News:Secure eHealth Partner Receives Patent and Notice of Patent Allowance that is Key to Enriched Data Portability in Healthcare 2Health News:Secure eHealth Partner Receives Patent and Notice of Patent Allowance that is Key to Enriched Data Portability in Healthcare 3Health News:CA$H-First(SM) LTCi Provides First-Day Cash Benefits at Affordable Rates 2Health News:Hanes(R) and Susan G. Komen for the Cure(R) Inspire Creativity for a Cause 2Health News:Hanes(R) and Susan G. Komen for the Cure(R) Inspire Creativity for a Cause 3Health News:Hanes(R) and Susan G. Komen for the Cure(R) Inspire Creativity for a Cause 4Health News:Aethlon Medical to Present at Today's Southern California Investor Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: